OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)
About the study
A 2-year, phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study. Primary efficacy will be determined at Week 52.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Active subfoveal CNV lesion or juxtafoveal CNV lesion with foveal involvement that is secondary to AMD in the Study Eye.
- An ETDRS BCVA score between 60 and 25 (inclusive) letters in the Study Eye.
EXCLUSION CRITERIA
Main Exclusion Criteria:
- Any previous treatment for neovascular AMD.
- Clinically significant ocular disorders (other than neovascular AMD), which may interfere with assessment of BCVA, assessment of safety, or fundus imaging.
- Any current (or history of a) social, psychological, or medical condition that precludes enrolment into the study.
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study Details
Contition
Neovascular Age-related Macular Degeneration
Age
50+
Phase
PHASE3
Participants Needed
990
Est. Completion Date
Jul 31, 2026
Treatment Type
INTERVENTIONAL
Sponsor
Opthea Limited
ClinicalTrials.gov NCT Identifier
NCT04757610
Study Number
OPT-302-1004
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?